Byrne · JAMA internal medicine 2022 · systematic review and meta-analysis · n=21 trials

Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.

Cited 112 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized clinical trials

PubMed 35285850 · doi:10.1001/jamainternmed.2022.0134 · record verified 2026-08-27

What was done

Search of PubMed and Embase (January 1987 to June 2021) for large randomized clinical trials comparing statins to placebo or usual care in adults with at least 2 years of planned follow-up and reported absolute LDL-C changes. Three reviewers assessed study quality using the Risk of Bias 2 tool and certainty using GRADE. Meta-analyses and meta-regression evaluated absolute and relative risk reductions for all-cause mortality, myocardial infarction, and stroke.

What was found

In 21 trials, statins reduced absolute risk by 0.8% (95% CI, 0.4%-1.2%) for all-cause mortality, 1.3% (95% CI, 0.9%-1.7%) for myocardial infarction, and 0.4% (95% CI, 0.2%-0.6%) for stroke. Associated relative risk reductions were 9% (95% CI, 5%-14%), 29% (95% CI, 22%-34%), and 14% (95% CI, 5%-22%), respectively. Meta-regression evaluating the mediating association of the magnitude of LDL-C lowering with outcomes was inconclusive.

Why it matters

Statin therapy yields modest absolute risk reductions for individual mortality and vascular outcomes despite substantially larger relative risk reductions. Presenting absolute risk changes is critical for informed shared decision-making in clinical practice.

Limits

Meta-regression could not establish a conclusive relationship between the degree of LDL-C reduction and individual clinical outcomes. Evidence certainty was downgraded due to significant heterogeneity across included studies. Total participant count was not reported in the abstract.

Cited by